TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04650724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T cell infusion agent targeting BCMA chimeric antigen receptor
Description: Chimeric antigen receptor T cells (car-t) is one of the most effective therapies for malignant tumors (especially hematological tumors). Like other immunotherapies, the basic principle is to use the patient's own immune cells to clear cancer cells. Chimeric antigen receptor (car) is the core component of car-t, which endows T cells with the ability to recognize tumor antigens in an independent manner, which enables car modified T cells to recognize a wider range of targets than natural T cell surface receptors (TCR). The basic design of car includes a tumor associated antigen binding region (usually derived from scFv segment of monoclonal antibody antigen binding region), transmembrane region and intracellular signal region. The selection of target antigen is a key determinant for the specificity and effectiveness of car and the safety of genetically modified T cells.
Study: NCT02941926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Ribociclib was centrally supplied to the investigators and administered orally once a day on days 1-21 of each 28 day cycle at a starting dose of 600 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole was procured locally and administered orally once a day on a continuous daily schedule at a dose of 2.5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin
Description: Goserelin was procured locally and administered in men and premenopausal women as an injectable subcutaneous implant administered on day 1 starting at Cycle 1 and then every 28 days at a dose of 3.6 mg (cycle = 28 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide
Description: Leuprolide was procured locally and administered in men and premenopausal women as an injectable intramuscular depot administered on day 1 starting at Cycle 1 and then every 28 days at a dose of 7.5 mg (cycle= 28 days)
Study: NCT03661125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saracatinib
Description: AZD0530 (Saracatinib) 50 mg Tablet Pink Round 7.0 mm ADM P/5406/49. Two tablets to be taken every morning for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saracatinib
Description: AZD0530 (Saracatinib) 50 mg Tablet Pink Round 7.0 mm ADM P/5406/49. Two tablets to be taken every morning for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Tablet
Description: Placebo AZD0530 (Saracatinib) 50 mg Tablet Pink Round 7.0 mm ADM P/5406/37. Two tablets to be taken every morning for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Tablet
Description: Placebo AZD0530 (Saracatinib) 50 mg Tablet Pink Round 7.0 mm ADM P/5406/37. Two tablets to be taken every morning for 14 days.
Study: NCT02693769

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone propionate/formoterol fumarate breath actuated inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone propionate/formoterol fumarate breath actuated inhaler

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indacaterol maleate / glycopyrronium bromide capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol maleate / glycopyrronium bromide capsules
Study: NCT01318720

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy
Description: Thrust manipulation is a type of manual therapy that clinicians apply using a high-velocity, low-amplitude thrust directed at a joint(s)
Study: NCT02376608

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pronova Pure 150:500 EE EU
Description: Each subject will participate in 4 treatment periods. The subjects are randomized to one of the following treatment sequences ABCD, BDAC, CADB, DCBA. 4 treatment free days between each treatment period

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pronova Pure 150:500 EE EU
Description: Each subject will participate in 4 treatment periods. The subjects are randomized to one of the following treatment sequences ABCD, BDAC, CADB, DCBA. 4 treatment free days between each treatment period

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pronova Pure 150:500 EE EU
Description: Each subject will participate in 4 treatment periods. The subjects are randomized to one of the following treatment sequences ABCD, BDAC, CADB, DCBA. 4 treatment free days between each treatment period

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pronova Pure 150:500 EE EU
Description: Each subject will participate in 4 treatment periods. The subjects are randomized to one of the following treatment sequences ABCD, BDAC, CADB, DCBA. 4 treatment free days between each treatment period

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pronovum PRF-037
Description: Each subject will participate in 4 treatment periods. The subjects are randomized to one of the following treatment sequences ABCD, BDAC, CADB, DCBA. 4 treatment free days between each treatment period
Study: NCT03666663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Nasal application using the Sphenocath device- cleared by FDA

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Saline using the Sphenocath device- cleared by FDA
Study: NCT03769064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Potential subjects will be screened to determine their eligibility for the study within 28 days of the first dose in the Qualification Phase (i.e., Days -28 to -2). Eligible subjects will be admitted to the clinical site on Day -1 of the Qualification Phase (Part 1) and randomized on Day 1 to receive placebo and MPH (60 mg) in 1 of 2 sequences with a 48-hour washout between dose administrations (i.e., dose administration on Days 1 and 3).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Potential subjects will be screened to determine their eligibility for the study within 28 days of the first dose in the Qualification Phase (i.e., Days -28 to -2). Eligible subjects will be admitted to the clinical site on Day -1 of the Qualification Phase (Part 1) and randomized on Day 1 to receive placebo and MPH (60 mg) in 1 of 2 sequences with a 48-hour washout between dose administrations (i.e., dose administration on Days 1 and 3).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate 60 mg
Description: Potential subjects will be screened to determine their eligibility for the study within 28 days of the first dose in the Qualification Phase (i.e., Days -28 to -2). Eligible subjects will be admitted to the clinical site on Day -1 of the Qualification Phase (Part 1) and randomized on Day 1 to receive placebo and MPH (60 mg) in 1 of 2 sequences with a 48-hour washout between dose administrations (i.e., dose administration on Days 1 and 3).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate 60 mg
Description: Potential subjects will be screened to determine their eligibility for the study within 28 days of the first dose in the Qualification Phase (i.e., Days -28 to -2). Eligible subjects will be admitted to the clinical site on Day -1 of the Qualification Phase (Part 1) and randomized on Day 1 to receive placebo and MPH (60 mg) in 1 of 2 sequences with a 48-hour washout between dose administrations (i.e., dose administration on Days 1 and 3).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment Phase Sequence 4213
Description: Subjects will be administered single doses on Days 1, 4, 7, and 10 of the Treatment Phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment Phase Sequence 2134
Description: Subjects will be administered single doses on Days 1, 4, 7, and 10 of the Treatment Phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment Phase Sequence 1342
Description: Subjects will be administered single doses on Days 1, 4, 7, and 10 of the Treatment Phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment Phase Sequence 3421
Description: Subjects will be administered single doses on Days 1, 4, 7, and 10 of the Treatment Phase.
Study: NCT01668719

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: Given SC or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given SC or IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Given PO or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO or IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Elotuzumab
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study: NCT00684229

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Regional anesthesia and analgesia
Description: Post-operative analgesia will be epidural bupivacaine and fentanyl as well as intravenous morphine.
Study: NCT04255238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemigliptin 50mg
Description: The subjects should visit a study site 6-7 times during the treatment period for about 24 weeks in total. - Background therapy should be administered keeping the same dosage administered before the study, according to the following criteria: Metformin ≥ 1,000 mg / day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemigliptin 50mg
Description: The subjects should visit a study site 6-7 times during the treatment period for about 24 weeks in total. - Background therapy should be administered keeping the same dosage administered before the study, according to the following criteria: Metformin ≥ 1,000 mg / day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10mg
Description: The subjects should visit a study site 6-7 times during the treatment period for about 24 weeks in total. - Background therapy should be administered keeping the same dosage administered before the study, according to the following criteria: Metformin ≥ 1,000 mg / day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10mg
Description: The subjects should visit a study site 6-7 times during the treatment period for about 24 weeks in total. - Background therapy should be administered keeping the same dosage administered before the study, according to the following criteria: Metformin ≥ 1,000 mg / day
Study: NCT03517878

Intervention type: BEHAVIORAL
Intervention: Comprehensive CHW Program
Description: The comprehensive CHW Cohort will receive home visits from CHWs recruited, trained, and supervised by the Philani organization. Philani has a 30-year history of non-stigmatizing home-based support for women and children in Cape Town. The organization has been operating their comprehensive CHW program in the rural Eastern Cape since 2010; however, in the research areas, CHWs have only been active for one year prior to initiation of the study. Philani recruits CHWs that are positive peer deviants to serve as role models in the community. The CHWs then receive training, materials, and skills to address major community health challenges of HIV, TB, malnutrition, alcohol use, and depression. The CHWs also receive ongoing monitoring and supervision as well as support for difficult cases.
Study: NCT01895413

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow aspiration
Description: Single intra-articular injection of autologous bone marrow-derived mesenchymal stem cells by arthroscopy
Study: NCT03527108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: The treatment will be given on a 28-day cycle, with doses of nivolumab and ramucirumab given on days 1 and 15. The dose of nivolumab will be fixed at 240 mg. Nivolumab should be administered first, followed by premedication, and then ramucirumab. Ramucirumab should be administered approximately 30 minutes after premedication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: The treatment will be given on a 28-day cycle, with doses of nivolumab and ramucirumab given on days 1 and 15. The dose of ramucirumab will depend upon the patient weight as noted below. Nivolumab should be administered first, followed by premedication, and then ramucirumab. Ramucirumab should be administered approximately 30 minutes after premedication
Study: NCT03008434

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assigned Interventions
Description: Yoga Group: designed for chronic TBI was provided two times a week for 8 weeks.
Study: NCT00684229

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: general anesthesia followed by opioid analgesia
Description: sevoflurane general anesthesia and postoperative opioid analgesia
Study: NCT04272541

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation program
Description: Intervention program consisted of psychopharmacology + psychoeducation. This will be executed during 3 months, distribuited in several sessions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Psychopharmacology intervention
Description: Intervention program consisted of psychopharmacology. This will be executed during 3 months.
Study: NCT03882242

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facilitation of a school-based program
Description: Participants deliver the prevention program (described in previous research) to school-children.
Study: NCT03702803

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Galphimia glauca standardized extract
Description: Each patient will be administered with a capsule once a day (in the morning), for 10 weeks. A capsule contains the standardized extract of Galphimia glauca corresponding to 0.374 mg of Galphimine-B

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alprazolam 1mg
Description: Each patient will be administered once a day (in the morning) for 10 weeks. A capsule contains 1 mg Alprazolam
Study: NCT04213014

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guys/Girls Opt for Activities for Life (GOAL)
Description: The 4 month (16-wk) GOAL intervention has 3 components: (1) After-school GOAL Club: 26 events (2 days/week; 120 min/event/day; 13 weeks due to no club during 3 school break weeks) for boys and girls to engage in physical activity and healthy eating and cooking activities; (2) Three parent-adolescent meetings (1st meeting at each school for parents and adolescents \[Zoom option if needed\]; 2nd and 3rd meetings delivered virtually and asynchronously for parents): to empower parents to assist adolescents with physical activity and healthy eating and cooking; and (3) GOAL social networking website: private website for parents to share with each other how they helped their adolescent increase physical activity and diet quality each week.
Study: NCT01499472

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: shock wave therapy
Description: shock wave therapy given in accordance to wound assessment every 2 weeks for 4 treatments.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: dermagold shockwave
Description: shock wave therapy given in accordance to wound assessment every 2 weeks for 4 treatments.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: standard of care
Description: regular care including debridement and bandaging.
Study: NCT01846325

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin E

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin E

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: DHA

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DHA

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT00387764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib
Description: 800 mg daily dosing continously until progression
Study: NCT01184053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arsenic trioxide
Description: Arsenic trioxide - 0.25 mg/kg/day for 5 consecutive days, every 4 weeks.
Study: NCT03099005

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabis
Description: vaporization of cannabis
Study: NCT04254458

Intervention type: DIAGNOSTIC_TEST
Intervention: Corneal densitometry
Description: Corneal density values were measured by densitometry software of Pentacam HR-Scheimpflug corneal topography
Study: NCT03925285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab-800CW
Description: Two to four days prior to surgery bevacizumab-800CW will be administered intravenously
Study: NCT04402034

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Application of tele-rehabilitation
Description: Individuals that will perform the virtual reality intervention.
Study: NCT03672578

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: loss-frame
Description: loss frame label

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: loss-frame
Description: loss frame label

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: loss-frame
Description: loss frame label

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: loss-frame
Description: loss frame label

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gain-frame
Description: gain frame label

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gain-frame
Description: gain frame label

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gain-frame
Description: gain frame label

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gain-frame
Description: gain frame label

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: text-only
Description: text-only label

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: text-only
Description: text-only label

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: text-only
Description: text-only label

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: text-only
Description: text-only label

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: icon
Description: label with icon and text
Study: NCT03099005

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabis
Description: vaporization of cannabis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabis
Description: vaporization of cannabis
Study: NCT05295316

Intervention type: OTHER
Intervention: Life Stressor Checklist Revised (LSC-R) (Appendix 1)
Description: Evaluation of stress factor as risk factor for fibromyalgia development

Intervention type: OTHER
Intervention: Life Stressor Checklist Revised (LSC-R) (Appendix 1)
Description: Evaluation of stress factor as risk factor for fibromyalgia development
Study: NCT00818181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biological: AL0206st
Study: NCT06441526

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anti-tumour necrosis factor α antibodies
Description: Biological drug

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Advancement plasty
Description: Surgical closure of the internal opening
Study: NCT00628173

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AGV implantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AGV implantation
Study: NCT02774551

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity intervention group
Description: 150 minutes of minimum intensity activity during a week (e.g. walking, swimming) and five strength training exercises (10 repetitions and 2 sets of: squats, wall push ups, rowing with resistance band, shoulder press with resistance band, hip abduction) targeting the major muscle groups to do twice a week.
Study: NCT02088788

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Board
Description: Also has radio-dense pelvic shielding

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: No Board
Description: Radio-lucent armboard for radial access with radio-dense drape across pelvis
Study: NCT01230853

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: A
Description: Lecanemab Single Dose Ascending Single intravenous infusions at sequentially ascending doses on Day 1 (dose levels: 0.1, 0.3, 1, 3, 10, and 15 mg/kg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator B
Description: Placebo Matching Placebo Infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator B
Description: Lecanemab Multiple Dose Ascending Intravenous infusions once every 4 weeks at sequentially ascending doses (dose levels: 0.3, 1, 3, and 10 mg/kg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator A
Description: Placebo Matching Placebo Infusion
Study: NCT01083628

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group CBT for Depression with MoodText
Description: Mobile phone based text messaging to inquire about mood, cognitions, and behaviors on a daily basis.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group CBT for Depression
Description: Standard group CBT for depression using BRIGHT manual
Study: NCT03792386

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guidance with fluoroscopic confirmation
Description: the cervical spine will be sonographically examined to determine the C7 transverse process then after lidocaine skin infiltration, a 22G spinal needle is directed towards the hypoechoic shadow of the nerve root using the in-plane technique. then 1ml of non-ionic contrast will be injected and AP and the oblique foraminal fluoroscopic view will be obtained. After confirmation of correct placement of the needle,(2ml, 8mg dexamethasone plus 1ml Lidocaine 1%) will be injected.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fluoroscopic guidance with ultrasonographic confirmation.
Description: After AP view, alignment or squaring of the target lower end plate, an oblique foraminal view is obtained. Following lidocaine 1% skin infiltration, a 22G spinal needle is directed towards the target foramen then, the superficial ultrasound probe will be applied to delineate the foramen. The needle will be advanced \~3mm towards the dorsal root ganglia under fluoroscopic guidance. After contrast confirmation of needle placement, 2ml,8mg dexamethasone plus 1ml Lidocaine 1%) will be injected.
Study: NCT04582981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib and raltitrexed
Description: Fruquintinib 5mg qd plus raltitrexed 2mg/m2, q2w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib
Description: Fruquintinib 5mg qd monotherapy